Background-Myofilament contractility of individual cardiomyocytes is depressed in remote noninfarcted myocardium and contributes to global left ventricular pump dysfunction after myocardial infarction (MI). Here, we investigated whether ␤-blocker therapy could restore myofilament contractility. Methods and Results-In pigs with a MI induced by ligation of the left circumflex coronary artery, ␤-blocker therapy (bisoprolol, MIϩ␤) was initiated on the first day after MI. Remote left ventricular subendocardial biopsies were taken 3 weeks after sham or MI surgery. Isometric force was measured in single permeabilized cardiomyocytes. Maximal force (F max ) was lower, whereas Ca 2ϩ sensitivity was higher in untreated MI compared with sham (both PϽ0.05). The difference in Ca 2ϩ sensitivity was abolished by treatment of cells with the ␤-adrenergic kinase, protein kinase A. ␤-blocker therapy partially reversed F max and Ca 2ϩ sensitivity to sham values and significantly reduced passive force. Despite the lower myofilament Ca 2ϩ sensitivity in MIϩ␤ compared with untreated myocardium, the protein kinase A induced reduction in Ca 2ϩ sensitivity was largest in cardiomyocytes from myocardium treated with ␤-blockers. Phosphorylation of ␤-adrenergic target proteins (myosin binding protein C and troponin I) did not differ among groups, whereas myosin light chain 2 phosphorylation was reduced in MI, which coincided with increased expression of protein phosphatase 1. ␤-blockade fully restored the latter alterations and significantly reduced expression of protein phosphatase 2a.
O ne of the principal risk factors for the development of heart failure in humans is myocardial infarction (MI), as it results in remodeling of the myocardium, consisting of left ventricular (LV) dilation and hypertrophy, with depressed global contractility. 1, 2 A number of factors, including changes in cardiac structure, apoptotic cell death, abnormal energy metabolism, and Ca 2ϩ handling disturbances have been implicated in the initiation and progression of heart failure on MI. 3, 4 Recently, it has been shown that cardiomyocyte contractile dysfunction in remote noninfarcted myocardium might contribute to global LV pump dysfunction following MI. [5] [6] [7] [8] 
Clinical Perspective on p 242
An acute myocardial ischemic insult leads to activation of the sympathetic nervous system to maintain perfusion of vital organs via peripheral vasoconstriction and restoration of cardiac output. However, chronic neurohumoral activation eventually has a negative impact on cardiac function, 9 as treatment of MI patients with ␤-blockers has been shown to improve LV dysfunction, slow the progression toward heart failure, and reduce the risk of sudden death. 9 -11 The beneficial effects of ␤-blockers are attributed to their ability to reduce heart rate and myocardial contractility leading to a reduction in myocardial workload and oxygen demand. 11 Moreover, ␤-blockers have been shown to reverse LV remodeling. 9, 12 However, it is unknown if and to what extent restoration of cardiomyocyte function contributes to the beneficial effects of ␤-blocker therapy post-MI.
In light of previous studies that demonstrated myofilament dysfunction in remodeled myocardium, 5, 8 we hypothesized that correction of myofilament contractile dysfunction contributes to the beneficial effects of ␤-blocker therapy after MI. To test this hypothesis, myofilament function and protein phosphorylation were studied in pigs with a MI induced by ligation of the left circumflex coronary artery (LCx). ␤-blocker therapy consisted of the selective ␤ 1 receptor antagonist bisoprolol (0.5 mg/kg/day per os) and was initiated on the first day after MI. Remote LV subendocardial biopsies were taken 3 weeks after MI in conjunction with echocardiographic and hemodynamic assessment of LV function at the time of biopsy procurement. To reveal the extent of the beneficial effects of ␤-blocker therapy MI groups were compared with sham-operated pigs.
The results of this study show that chronic ␤-blocker therapy after MI largely prevents myofilament dysfunction and cellular hypertrophy, which explains at least part of its clinical benefit in patients with a recent MI.
Methods

MI and ␤-Blocker Therapy
Experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publication 86 to 23, revised 1996) , and with approval of the Animal Care Committee of the Erasmus Medical Center. Twenty-five 2 to 3 month-old Yorkshire-Landrace pigs of either sex entered the study. Pigs were sedated (ketamine, 20 mg/kg intramuscularly (IM), and midazolam, 0.5 mg/kg IM), anesthetized (thiopental, 10 mg/kg intravenously [IV]), intubated and ventilated with O 2 and N 2 O to which 0.1% to 1% (vol/vol) isoflurane was added. 5 Anesthesia was maintained with midazolam (2 mg/kg followed by 1 mg/kg per hour IV) and fentanyl (10 g/kg per hour IV). Under sterile conditions, the chest was opened via the fourth left intercostal space and a 4-cm incision was made in the pericardium at the site of the origin of the LCx. The LCx was dissected out and a suture was placed around it. The LCx was permanently ligated to produce a MI (nϭ17), whereas in the animals from the sham group (nϭ8) the suture was removed. The chest was closed and the animals were allowed to recover, receiving analgesia (0.3 mg buprenorphine IM) for 2 days and antibiotic prophylaxis (25 mg/kg amoxicillin and 5 mg/kg gentamycin IV) for 5 days. 5 Before induction of infarction, MI pigs were randomly assigned to receive no treatment (MI, nϭ9) or ␤-blocker treatment with bisoprolol (MIϩ␤, nϭ8), excluding any bias toward differences in acute infarct size between the 2 MI groups. Bisoprolol was administered orally by mixing bisoprolol powder with regular pig chow. The drug was started at a dosage of 0.125 mg/kg per OS and increased (by 0.125 mg/kg per day) in three days to a dosage of 0.5 mg/kg p.o. per day. This dosage was maintained until the day before euthanization. Because pigs lack a native coronary collateral circulation, myocardial infarct size reaches its plateau at Ϸ90% of the risk area within 2 hours after onset of coronary ligation. 13, 14 To prevent a potential effect of ␤-blockade on acute infarct size, bisoprolol treatment was initiated at Ϸ24 hours after the onset of permanent LCx ligation.
Six animals died during the period before euthanization. One sham and 2 MI pigs (one MI and MIϩ␤) died during the surgical procedures or overnight after surgery, ie, before treatment initiation. One animal (MI group) died at 1 week after surgery, and 2 animals died on the day of euthanization due to acute pump failure, one after sedation (MI group) and one after induction of anesthesia (MIϩ␤ group). Thus the number of animals included in this study amounted to 7 in the sham group, 6 in the MI group and 6 in the MIϩ␤ group.
In Vivo Measurements and Storage of Cardiac Tissue Samples
Three weeks after surgery, pigs were sedated (ketamine, 20 mg/kg IM, and midazolam, 0.5 mg/kg IM). 2D echocardiographic recordings of the LV short axis at midpapillary level were obtained (ALOKA ProSound SSD-4000; Japan) and stored for off-line analysis. 5 LV end-diastolic cross-sectional area (EDA) and end-systolic cross-sectional area (ESA) were determined, and ejection fraction (EF) was calculated as (EDAϪESA)/EDAϫ100%. Subsequently, pigs were anesthetized (pentobarbital, 20 mg/kg IV), intubated and ventilated with O 2 and N 2 . 5 Anesthesia was maintained with pentobarbital (10 to 15 mg/kg per h IV). Animals were instrumented to allow closed-chest monitoring of heart rate, cardiac output, mean aortic and pulmonary artery blood pressures, and LV pressure, its first derivative dP/dt at LV pressure of 40 mm Hg (LVdP/dt P40 ) and the time constant of exponential LV pressure decay (tau). 5 Then, a midline sternotomy was performed and the heart was suspended in a pericardial cradle. To determine myofilament function and protein phosphorylation, 2 to 3 thru-cut (transmural, 5 to 10 mg wet weight) needle biopsies were taken from the LV anterior free wall myocardium (in MI pigs: remodeled noninfarcted tissue) and immediately frozen and stored in liquid nitrogen. Subsequently, hearts were arrested, quickly excised, and subendocardial samples were frozen in liquid nitrogen for histologic analysis of cross-sectional cardiomyocyte area. 15
Cardiomyocyte Measurements
Single cardiomyocytes were obtained via mechanical isolation 16 from the subendocardial half of the biopsies and incubated for 5 minutes with Triton X-100 (0.5%) to remove all membranes. Isometric force was measured at various calcium concentrations at 15°C and sarcomere length of 2.2 m. Passive force development was measured at sarcomere lengths of 1.8, 2.0, and 2.2 m. Composition of solutions used for cell isolation and force measurements have been described in detail previously. 16 In a number of cells force measurements were repeated after incubation with the catalytic subunit of protein kinase A (PKA, 40 minutes; 20°C; 100 U/mL; Sigma). In addition, force measurements were repeated on incubation with protein phosphatase 1 (PP1, 60 minutes; 20°C; 0.5 U/mL; 14 to 110; Upstate) in a number of sham cardiomyocytes.
Myofilament Protein Composition
ProQ Phosphostaining
Subendocardial tissue (Ϸ0.5 to 1.0 mg dry weight) from needle biopsies was TCA (trichloro acetic acid)-treated as described previously. 17 Phosphorylation status of myofilament proteins was determined using Pro-Q Diamond phosphostaining (Molecular Probes). Samples were separated on a gradient gel (Criterion Tris-HCl 4% to 15% gel, BioRad) and proteins were stained for one hour with Pro-Q Diamond Phosphoprotein Stain. Fixation, washing, and destaining were performed according to the manufacturer's guidelines. Staining was visualized using the LAS-3000 Image Reader (FUJI; 460 nm/605 nm Ex/Em; 2 minutes illumination) and signals were analyzed with AIDA. All protein signals were within the linear range. Subsequently, gels were stained overnight with SYPRO Ruby stain (Molecular Probes) and visualized with the LAS-3000 (460 nm/605 nm Ex/Em; 2 s illumination). Because illumination of Pro-Q Diamond-stained gels for 2 s did not reveal any signal, the signals obtained on SYPRO Ruby staining are not tainted by Pro-Q signals.
Effect of PP 1 on Myofilament Protein Phosphorylation
Triton-treated (0.5%) sham samples (1 mg dry weight) were incubated with PP1 and subsequently treated with TCA and analyzed using Pro-Q Diamond stained gradient gels as described earlier.
Differential Myosin Binding Protein C Phosphorylation
Cardiac myosin binding protein C (cMyBP-C) composition was analyzed by 2D-gel electrophoresis as described recently by Yuan et al. 18 Approximately 75 g of biopsy tissue was loaded and proteins were stained with SYPRO Ruby.
Western Immunoblotting
Gel electrophoresis and Western immunoblotting was performed to analyze phosphorylation (at Ser-23/24, ie, PKA sites, rabbit polyclonal Ab, dilution 1:500, Cell signaling) and degradation (clone 8I-7, mouse monoclonal Ab, dilution 1:1000, Spectral Diagnostics) 5 of cardiac troponin I (cTnI). The following antibodies were used to detect degradation/expression of cMyBP-C (C0C2, rabbit polyclonal Ab, diluted 1:1000; kindly provided by Dr. S. Winegrad, University of Pennsylvania, Philadelphia, Pa), cardiac troponin T (cTnT, JLT12, mouse monoclonal Ab, diluted 1:250, Sigma) and myosin light chain 2 (MLC-2, F109.3E1, mouse monoclonal Ab, diluted 1:200, Alexis biochemicals), phosphorylation of cMyBP-C (P-cMyBP-C, Ser-282, rabbit polyclonal Ab, dilution 1:1000), protein kinase C ␣ expression (PKC␣, 664 to 672, rabbit polyclonal Ab, dilution 1:500, Research & Diagnostic Antibodies) and activity (p-PKC␣, Ser-657, sc-12356, rabbit polyclonal Ab, dilution 1:200, Santa Cruz Biotechnology), expression level of PP 1 (sc-7482, mouse monoclonal Ab, dilution 1:200, Santa Cruz Biotechnology) and PP 2a (PP2a, rabbit polyclonal, dilution 1:500, Upstate). Signals were normalized to actin to correct for differences in protein loading. For normalization of PP2a calsequestrin was used (CSQ, rabbit polyclonal, dilution 1:2000; Santa Cruz Biotechnology).
Titin Isoform Composition
Heart tissue was homogenized in modified Laemmli buffer, proteins were separated on Agarose-strengthened 2% SDS-PAGE as described previously. 19 Protein bands were visualized by Imperial protein stain, scanned, and analyzed densitometrically.
Statistical Analysis
Data are given as meansϮSEM. Data of the three experimental groups (sham, MI and MIϩ␤) were compared using 1-way ANOVA and post hoc Bonferroni analysis. Effects of PKA and PP1 were tested by paired Student t tests. Significance was accepted when PϽ0.05.
Results
Improvement of Global LV Function by Early ␤-Blocker Therapy
Three weeks after infarction, significant LV remodeling had occurred, reflected by LV dilation and hypertrophy of the surviving myocardium (Table) . Thus, despite loss of Ϸ25% of viable myocardium, LV weight was maintained whereas a 20% increase in cardiomyocyte cross-sectional area was observed in MI compared with sham. LV systolic dysfunction was reflected in lower levels of ejection fraction and stroke volume (Table) . The consequent decrease in cardiac output resulted in elevated LV end-diastolic pressure and elevated pulmonary artery pressure that was associated with a trend toward an increase in right ventricle weight.
Treatment of MI pigs with bisoprolol had no significant effects on LV mass or lumen area. However, bisoprolol lowered heart rate and fully restored stroke volume, so that the MI-induced decrease in cardiac output was prevented (Table) .
Improvement of Myofilament Function by Early ␤-Blocker Therapy
Similar to our previous observations 5 maximal force development (F max ; Figure 1A ) of cardiomyocytes isolated from post-MI remodeled hearts was significantly decreased by 47% compared with sham, whereas myofilament responsiveness to Ca 2ϩ was significantly increased as illustrated by the leftward shift of the force-calcium relation and the lower EC 50 and in MI ( Figure 1C and 1D ). ␤-blocker therapy partially reversed the reductions in F max and EC 50 in MI, whereas passive force (F pas ) was significantly reduced at a sarcomere length of 2.2 m compared with both sham and untreated MI ( Figure 1B ). The steepness of the force-calcium relation (nHill) did not significantly differ among the three groups (nHill: 3.49Ϯ0.11, 3.16Ϯ0.18, and 3.38Ϯ0.20 in sham, MI and MIϩ␤, respectively).
To assess whether the effects on cardiomyocyte force characteristics are related to differences in ␤-adrenergic signaling among the three groups, force measurements were repeated after incubation with exogenous PKA. F max slightly (Ϸ10%) but significantly increased in sham and MIϩ␤ on PKA, whereas it did not change in untreated MI. Hence, the difference in F max between groups remained (Figure 2A ). F pas was significantly reduced after PKA in MIϩ␤ cells and remained lower compared with MI and sham cells ( Figure  2B ). In all groups, PKA significantly reduced Ca 2ϩ sensitivity of the myofilaments, but analogous to the effect on F max the shift in EC 50 varied among the groups, being smallest in sham cells and largest in MIϩ␤ cells ( Figure 2C ). Post hoc Bonferroni analysis showed that PKA abolished the difference in Ca 2ϩ sensitivity between sham and MI cells, whereas EC 50 was significantly higher in MIϩ␤ compared with MI cells (Figure 2C and 2D) . Steepness of the force-Ca 2ϩ 
Unaltered Phosphorylation of Target Proteins of the ␤-Adrenergic Pathway
To investigate whether changes in myofilament protein phosphorylation may explain the differences in myofilament force characteristics, proteins were separated on 1D gradient gels and stained with Pro-Q Diamond ( Figure 3A ) and SYPRO Ruby ( Figure 3B ). Phosphorylation status of cMyBP-C, and cTnI, the major target proteins of PKA, did not differ among the three groups. In addition, no difference was seen in desmin and cardiac troponin T (cTnT) phosphorylation (Figure 3C) . Western immunoblot analysis with a specific anti-body directed against phosphorylated PKA-sites in cTnI did not reveal a significant difference among the groups. Similarly, analysis of cMyBP-C phosphorylation at Ser-282 did not differ among the three groups (data not shown). In contrast, MLC-2 phosphorylation was lower in MI than in sham ( Figure 3C ). Differences in myofilament F max have been associated with changes in cMyBP-C phosphorylation, involving Ca 2ϩ -regulated and PKA-mediated phosphorylation. 20 Thus, although no significant differences were observed in total cMyBP-C phosphorylation, cMyBP-C could be differentially phosphorylated by the combined actions of kinases and phosphatases. To resolve this issue, cMyBP-C was separated by 2D-gel electrophoresis ( Figure 4A ). In agreement with the observation by Yuan et al 18 Effect exogenous PKA. PKA treatment of cells significantly increased F max in sham (nϭ5) and MIϩ␤ (nϭ9) cells, whereas it had no effect in MI (nϭ5) (A). PKA significantly reduced F pas in MIϩ␤ (B). PKA increased EC 50 in all groups (C). The PKA-induced shift in EC 50 was significantly different among groups and abolished the difference in EC 50 between sham and MI cells, whereas EC 50 was significantly higher in MIϩ␤ than in MI cardiomyocytes after PKA (C, D). *PϽ0.05, MI versus sham;
in dog
†PϽ0.05, MIϩ␤ versus MI in post test Bonferroni analysis. ‡PϽ0.05, before versus after PKA in paired t test. n indicates number of cardiomyocytes. myocardium, multiple spots were found at the level of cMyBP-C ( Figure 4A and 4B) , which represent differentially phosphorylated forms. No significant difference was found in the pattern of cMyBP-C spots among the 3 groups as shown in Figure 4C .
Absence of Myofilament Protein Degradation
Previously, minute amounts of a cTnI degradation product were found in postinfarct remodeled myocardium. 5 Western immunoblot analysis using clone 8I-7, which is directed against the central region of cTnI, did not reveal degradation of cTnI in any of the subendocardial needle biopsies ( Figure  5A ). Moreover, no degradation products were observed for cMyBP-C, cTnT, and MLC-2 ( Figure 5B ). As the reduced phosphorylation of MLC-2 in MI ( Figure 3C ) may be the resultant of reduced MLC-2 expression, expression of MLC-2 protein was determined relative to Ponceau-stained actin. MLC-2 expression was similar in all groups ( Figure 5C ), and therefore does not underlie alterations in MLC-2 phosphorylation. Similarly, expression of cTnI, cMyBP-C and cTnT (relative to Ponceau-stained actin) did not differ among groups (not shown).
Unaltered Titin Isoform Composition
To investigate whether a shift in titin isoform composition underlies the reduction in F pas observed in MIϩ␤, the stiff N2B and compliant N2BA titin isoforms were analyzed using SDS-PAGE. The percentage of the more compliant N2BA titin isoform did not significantly differ among groups ( Figure 5D ). were separated on a 4% to 15% gradient gel stained with Pro-Q Diamond (A). The gels were subsequently stained with SYPRO Ruby (B). ProQ diamond stained signals (cardiac myosin binding protein C, cMyBP-C; desmin; cardiac troponin T, cTnT; cardiac troponin I, cTnI and MLC-2) were divided by the SYPRO-stained cMyBP-C protein band to correct for differences in protein loading. M indicates molecular weight marker (PeppermintStick Phosphoprotein marker in which ovalbumin and ␤-casein are phosphorylated); MHC, myosin heavy chain. One-way ANOVA did not reveal significant differences among the three groups in phosphorylation status of cMyBP-C, desmin, cTnT and cTnI, whereas MLC-2 phosphorylation was significantly lower in MI compared with sham (C). *PϽ0.05, MI versus sham in post test Bonferroni analysis. In addition, no degradation products were found for cMyBP-C, cTnT, and MLC-2 (B). Protein expression of MLC-2 relative to Ponceau-stained actin did not differ among groups (C). No differences were found in titin isoform composition (D).
Increased PP1 in MI and Reduced PP2a on ␤-Blockade
Recently, Belin et al 21 showed that augmented PKC␣induced protein phosphorylation might contribute to myofilament dysfunction in congestive heart failure. Western immunoblot analysis did not reveal differences in PKC␣ expression (relative to ponceau-stained actin: 0.36Ϯ0.10, 0.29Ϯ0.02, and 0.31Ϯ0.03) and activity (ie, p-PKC␣: 1.11Ϯ0.13, 1.15Ϯ0.24, and 1.18Ϯ0.28) between sham, MI and MIϩ␤, respectively (nϭ5 in all groups). In contrast analysis of protein phosphatases revealed a significantly increased PP1 expression in MI by 80% compared with sham, which was prevented by ␤-blockade ( Figure 6A ) and a significant reduction in PP2a in MI treated with ␤-blockers ( Figure 6B ).
PP1 Increases Myofilament Ca 2؉ Sensitivity
To investigate if altered baseline force characteristics in MI (ie, reduced F max and reduced EC 50 ; Figure 1A and 1D) may be the resultant of increased PP1 force was measured in sham cardiomyocytes before and after PP1 treatment. PP1 slightly increased F max (Pϭ0.07; Figure 7A ), but did not alter F pas (before versus after: 4.9Ϯ0.7 and 4.5Ϯ0.7 kN/m 2 ). Ca 2ϩ sensitivity significantly increased on PP1 treatment illustrated by the reduction in EC 50 ( Figure 7A ), similar to the value observed in MI ( Figure 1D ). In addition, a significant decrease was observed in nHill (before versus after: 3.64Ϯ0.17 and 3.09Ϯ0.13).
Pro-Q Diamond staining ( Figure 7B ) of sham myocardium incubated with and without PP1 revealed a reduction in MLC-2 phosphorylation by 71% ( Figure 7C ). PP1 also decreased cTnI phosphorylation by 45%, whereas the effects on phosphorylation of the other proteins (cMyBP-C, desmin, and cTnT) were only minor.
Discussion
The present study was designed to determine the effects of ␤-blocker therapy on cardiomyocyte function after MI in a large animal model. Early ␤-blocker treatment attenuated global LV dysfunction after MI. At the cardiomyocyte level, ␤-blockade blunted not only the MI-induced cardiomyocyte hypertrophy but also prevented the MI-induced decrease in maximum force development and increase in myofilament Ca 2ϩ sensitivity. The implications of these findings and their molecular underpinnings are discussed in detail.
␤-Blocker Therapy Improved Cardiomyocyte Function After MI
Maximal Force Development
In accordance with previous studies, [5] [6] [7] [8] our data indicate that a reduction in maximal force generating capacity (F max ) of single permeabilized noninfarcted cardiomyocytes may contribute to systolic dysfunction of remodeled myocardium. Different mechanisms have been implicated in the reduction of F max , including cTnI degradation. 5 Degradation of cTnI could result from intermittent subendocardial ischemia, due to recurrent subendocardial hypoperfusion during increased physical activity, 1 or could be stretch-mediated secondary to the increased LV end-diastolic pressures. 22 However, using selective exchange of endogenous full length cTnI by truncated cTnI, Narolska et al 23 did not observe an effect on maximal force. Moreover, in the present study (using an in vivo needle biopsy approach that allows faster procurement of subendocardial tissue compared with the ex vivo approach in our previous study 5 ) we did not observe any cTnI degradation ( Figure 5A ) in remote myocardium of MI pigs, or degradation products for cMyBP-C, cTnT or MLC-2 ( Figure  5B ). On the basis of these data we conclude that reduced F max in remodeled myocardium is not caused by protein proteolysis.
Alternatively, the decrease in F max could be the result of neurohumoral activation. 5, 21 We have previously shown 5 that in vivo cardiac responsiveness to the aggravated exerciseinduced increases in noradrenaline was blunted in pigs with a MI, consistent with downregulation, uncoupling and/or downstream signaling defects of the ␤-adrenergic receptors. Stimulation of the ␤-adrenergic pathway activates PKAmediated phosphorylation of the sarcomeric proteins cMyBP-C, cTnI and titin, 24, 25 of which cMyBP-C has been proposed to exert an effect on the maximal force generating capacity of myofilaments. 20 Recently, reduced cMyBP-C phosphorylation was observed in human heart failure. 26, 27 and altered cMyBP-C phosphorylation has been implicated in contractile dysfunction. 18 However, in the present study phosphorylation level of cMyBP-C did not differ among groups and exogenous PKA did not enhance F max in MI. In a previous study McClellan et al 20 observed that phosphorylation of cMyBP-C by Ca 2ϩ -calmodulin-dependent kinase was prerequisite for a PKA-mediated increase in F max . Moreover, phosphorylation at Ser-282 enables cMyBP-C phosphorylation at other sites. 28 As exogenous PKA significantly increased F max only in sham and ␤-blocker treated MI pigs, differential cMyBP-C phosphorylation might explain the differences in F max . Our 2D analysis of MyBP-C did however not reveal diverse phosphorylation patterns among the three groups. Moreover, phosphorylation at Ser-282 did not differ among the groups. Taken together, these findings indicate that alterations in cMyBP-C phosphorylation do not underlie the reduction in F max in remote myocardium, and cannot explain the positive effect of ␤-blockade thereon.
Impaired cardiac function has been ascribed to increased expression and activity of PKC isoforms in myocardial disease. 21, 29, 30 In particular PKC-mediated phosphorylation of troponin subunits has been implicated in reduced maximal force production of myofilaments. [31] [32] [33] Recently, Belin et al 21 observed upregulation of PKC␣, increased cTnI phosphorylation, 6 preserved PP1 expression, and a reduction in F max and in myofilament Ca 2ϩ sensitivity in a rat model of end-stage congestive heart failure Ϸ34 weeks after MI. Myofilament dysfunction was largely reversed by exogenous PP1 treatment, indicative for hyperphosphorylation of myofilament proteins. 21 However, myofilament function was unaltered early after MI (Ϸ12 weeks), 21 which contrasts with our data. In our pig model, a reduction in F max in remodeled myocardium 3 weeks after MI coincided with reduced phosphorylation of MLC-2 and increased PP1 expression, whereas no differences were found in basal phosphorylation of cTnT and cTnI. Moreover, no difference was found in PKC␣ expression and activity, and previous analysis of differential cTnT phosphorylation with 2D-gel electrophoresis did not reveal differences between MI and sham. 5 The increased expression of PP1 implies that hypophoshorylation rather than hyperphoshorylation could be involved in altered myofilament contractility. The increase in PP1 is consistent with previous observations in failing human myocardium, in which increased PP1 activity has been observed. 34 ␤-blockers lowered expression levels of both PP1 and PP2a and reversed the reduction in MLC-2 phosphorylation. Hence, restoration of F max by ␤-blockade may be explained by alterations in phosphatase rather than in kinase activities.
Ca 2؉ Sensitivity
In healthy myocardium, myofilament protein phosphorylation by PKA reduces myofilament Ca 2ϩ sensitivity on adrenergic stimulation and thereby exerts a positive lusitropic effect. [35] [36] [37] The increased myofilament Ca 2ϩ sensitivity in post-MI remodeled myocardium is thought to originate from reduced ␤-adrenergic mediated cTnI and cMyBP-C phosphorylation. 38, 39 Accordingly, treatment of cardiomyocytes with exogenous PKA induced a larger shift in EC 50 in MI compared with sham and abolished the initial difference in Ca 2ϩ sensitivity. ␤-blockade largely prevented the enhanced myofilament Ca 2ϩ sensitivity, suggesting that defective PKA signaling was prevented. Surprisingly, however, PKA responsiveness was further enhanced in MI pigs receiving ␤-blockade. Moreover, the increase in PKA responsiveness in MI pigs either without or with ␤-blockade could not be explained by alterations in cMyBP-C phosphorylation or in cTnI phosphorylation. Taken together these findings suggest that the beneficial effects of ␤-blockade on Ca 2ϩ sensitivity occurred independently of alterations in PKA signaling and phosphorylation of its myofilament target proteins cMyBP-C and cTnI.
Passive Force
The decrease in LV end diastolic pressure in the ␤-blocker treated pigs may, at least in part, be the result of reduced cardiomyocyte stiffness. 16 The latter could not be explained by a shift in titin isoform composition. PKA-mediated phosphorylation of titin has been shown to reduce passive force development. 25 Moreover, the PKA-mediated F pas reduction depends on isoform composition, as it is larger in tissue expressing predominantly stiff N2B titin isoform. 40 The ␤-blocker induced decrease in F pas may involve augmented phosphorylation status of titin isoforms resulting from reductions in both PP1 and PP2a and warrants further research. 41
Importance of Phosphatases in Altered Myofilament Function
A recent study in rats with ischemic heart failure 42 Similarly, in MI mice, exercise prevented the reduction in F max , which was associated with an increase in MLC-2 phosphorylation. 8 Thus, the reduction in maximal force generating capacity of myofilaments may be due to reduced MLC-2 phosphorylation post-MI. To reveal if altered myofilament function and reduced MLC-2 phosphorylation in post-MI remodeled myocardium can be explained by the increased PP1 expression, sham myocardium was treated with exogenous PP1. PP1 decreased MLC-2 phosphorylation and lowered EC 50 in sham cells ( Figure 7A ) to the value observed in MI cardiomyocytes ( Figure 1D) . Thus, the increase in PP1 in MI myocardium may underlie enhanced Ca 2ϩ sensitivity and reduced MLC-2 phosphorylation. However, F max remained unaltered. The absence of an affect on F max , may be explained by the fact that exogenous PP1 treatment did not solely dephosphorylate MLC-2, but also lowered cTnI phosphorylation. Similarly, PP1 treatment of human cardiac tissue reduced phosphorylation of MLC-2 and cTnI, whereas PP2a only reduced cTnI. 17 To fully understand the consequences of altered PPs for myofilament function, it remains to be investigated which myofilament proteins are targets for PPs in vivo.
Rather than a direct effect of phosphatase on cellular target proteins, PP2a has been shown to alter phosphorylation of the calcium handling protein phospholamban via regulation of inhibitor-1 (I-1), the protein inhibitor of PP1. 43 Inhibitor-1, which phosphorylation status is regulated by kinases 30, 44 and phosphatases, 43 plays a pivotal role in the phosphorylation/ dephosphorylation balance. 45 PKA-mediated phosphorylation of I-1 on ␤-AR stimulation augments blockade of PP1, shifting the balance to phosphorylation. 46 Alternatively, PP2a dephosphorylates and inactivates I-1 43 and thereby releases blockade of PP1, shifting the balance to dephosphorylation. In line with these observations, increased PP1 expression as observed in MI would counteract ␤-AR signaling, whereas the ␤-blockade induced decrease in PP2a would enhance ␤-AR responsiveness via augmented phosphorylation of I-1. The latter corresponds with the enhanced myofilament responsiveness to exogenous PKA in MI treated with ␤-blockers. Future investigations are warranted to explore the effects of chronic ␤-blockade on ␤-adrenergic receptor responsiveness of intact cardiomyocytes and to determine the role of I-1 and its phosphorylation status in the effects of chronic ␤-blockade.
Methodological Considerations
Because the acute effect of ␤-blockade in post-MI remodeled pig hearts is a reduction in global LV function, 47 it follows that an improvement in LV pump function produced by chronic ␤-blockade must stem from molecular alterations at the cardiomyocyte level. Interestingly, we did not observe a significant effect of ␤-blockade on global LV remodeling or cardiomyocyte hypertrophy, consistent with the concept that chronic ␤-blockade acted through a primary effect on cardiomyocyte (ie, myofilament) function that resulted in an improvement of global LV function. Nevertheless, it must be acknowledged that in addition to the correction of myofila-ment dysfunction, several other mechanisms may also have contributed to the beneficial effect of ␤-blocker therapy on cardiac performance after MI. For example, we have previously shown that apoptosis and interstitial collagen deposition are increased in post-MI remodeled myocardium, 8 blunting of which could have contributed to the favorable effects of ␤-adrenergic receptor blockade. Similarly, it could be speculated that ␤-blocker therapy may have acted in part via restoring myocardial oxygen balance within the remodeled myocardium. 1, 48 Finally, correction of impaired calcium handling may improve cardiomyocyte contractility. We did not observe changes in expression of SERCA2a and phospholamban among groups (data not shown), but cannot exclude that alterations in phosphorylation status of calcium handling proteins contributed to an improvement in calcium handling. These issues should be subject of further studies.
Conclusions and Clinical Implications
The present study demonstrates that ␤-blocker therapy prevents myofilament dysfunction of surviving cardiomyocytes in a large animal model of post-MI remodeling. Furthermore, ␤-blockade reduced passive cardiomyocyte stiffness and enhanced the myofilament Ca 2ϩ responsiveness to exogenous PKA stimulation, which may benefit in vivo myocardial relaxation during increased cardiac stress. Our data indicate that enhanced protein phosphoryation by altered expression levels of PPs underlie restoration of myofilament dysfunction and reduced passive stiffness at the cellular level. These beneficial effects likely contribute to the observed improvements in global LV function in clinical investigations. 2, 49, 50 
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CLINICAL PERSPECTIVE
One of the principal risk factors for the development of heart failure in humans is myocardial infarction (MI) as it results in remodeling of the remote myocardium, with depressed global contractility. An acute MI leads to activation of the sympathetic nervous system to maintain perfusion of vital organs via peripheral vasoconstriction and restoration of cardiac output. However, chronic neurohumoral activation eventually has a negative impact on cardiac function, as treatment of MI patients with ␤-blockers has been shown to improve left ventricular dysfunction, slow the progression towards heart failure and reduce the risk of sudden death. The beneficial effects of ␤-blockers are attributed to their ability to reduce heart rate and myocardial contractility leading to a reduction in myocardial workload and oxygen demand. In this study, we investigated if restoration of cardiomyocyte function contributes to the beneficial effects of ␤-blocker therapy after MI. Cardiomyocyte function was studied in pigs with a MI induced by ligation of the left circumflex coronary artery. ␤-blocker therapy consisting of the selective ␤ 1 receptor antagonist bisoprolol was initiated on the first day after MI. ␤-blocker therapy prevented myofilament dysfunction of cardiomyocytes in remote, remodeled areas. Furthermore, ␤-blockade reduced cardiomyocyte stiffness and enhanced myofilament Ca 2ϩ responsiveness to exogenous protein kinase A, which mimics ␤-adrenergic stimulation. This may improve myocardial relaxation during increased cardiac stress. Our study shows that chronic ␤-blocker therapy largely prevents myofilament dysfunction and cellular hypertrophy, which explains at least part of its clinical benefit in patients with a recent MI.
